推进浙江省免疫治疗产业发展的对策研究  

Countermeasure Research on Promoting the Development of Immunotherapy Industry in Zhejiang Province

作　　者：林志坚[1] 周元 徐飞虎[2] 吕国昌[1] 应向伟[1] LIN Zhi-jian;ZHOU Yuan;XU Fei-hu;LV Guo-chang;YING Xiang-wei(Zhejiang Institute of Scientific and Technological Information,Hangzhou 310052;Hangzhou Jiuyuan Gene Engineering Co.,Ltd.,Hangzhou 310018)

机构地区：[1]浙江省科技信息研究院,杭州310052 [2]杭州九源基因工程有限公司,杭州310018

出　　处：《全球科技经济瞭望》2020年第4期69-76,共8页Global Science，Technology and Economy Outlook

基　　金：国家知识产权局专利战略推进工程项目“肿瘤精准靶向治疗药物——免疫检查点抑制剂抗体开发专利战略研究”(PS2017-006)。

摘　　要：免疫治疗技术代表着癌症治疗的未来发展方向,全球已进入快速发展阶段。PD-1/PD-L1抗体药物通过调动自身免疫系统功能,抗击癌细胞,而非通过外来药物作用杀死癌细胞,不仅能抑制癌细胞的增长,同时也会增强自身免疫力。本文以PD-1/PD-L1抗体为切入点,通过专利分析、文献和实地调研,揭示了国内外主要生物医药企业的PD-1/PD-L1药物研发专利布局情况,包括药物开发、组合疗法和下游标志物等,明确该领域的发展方向,理清产品和技术之间的关系。并以浙江省为例,为地方政府精准切入免疫治疗新兴产业、抢占全球生物医药产业制高点提出对策建议。Immunotherapy technology represents the future direction of cancer treatment and has entered a stage of rapid development.PD-1/PD-L1 antibodies can not only inhibit the growth of cancer cells,but also enhance the autoimmunity by mobilizing the function of the autoimmune system to fight against cancer cells,rather than killing cancer cells through the action of foreign drugs.In this paper,the development of PD-1/PDL1 antibodies is analyzed.Through patent analysis,literature and field research,the patent layout of PD-1/PDL1 antibodies of leading companies at home and abroad is revealed,including drug development,combination therapy and downstream biomarkers,to clarify the relationship between product and technology.Taking Zhejiang Province as an example,this paper puts forward countermeasures and suggestions for local governments to precisely cut into this emerging industry and seize the commanding heights of global biomedical industry.

关 键 词：免疫治疗 PD-1 PD-L1 专利分析 SWOT分析 人才地图 

分 类 号：G306[文化科学] R392[医药卫生—免疫学]